Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 327

Results For "EU"

5448 News Found

Zydus receives final approval from the USFDA for Azithromycin Tablets
Drug Approval | April 11, 2023

Zydus receives final approval from the USFDA for Azithromycin Tablets

Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States


Calibre Chemicals takes over R&D activities of Tina Life Sciences
News | April 11, 2023

Calibre Chemicals takes over R&D activities of Tina Life Sciences

Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.


AIIA hosts walkthrough for Working Group of C20 on Integrated Holistic Health
News | April 10, 2023

AIIA hosts walkthrough for Working Group of C20 on Integrated Holistic Health

MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda


Thermo Fisher Scientific expands its capabilities in France
News | April 10, 2023

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations


Virpax reports on progress of Envelta
Drug Approval | April 10, 2023

Virpax reports on progress of Envelta

Envelta is the company’s non-opioid pain product candidate for acute and chronic pain


Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData
News | April 08, 2023

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop


mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA
Drug Approval | April 07, 2023

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma


Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product
News | April 06, 2023

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution